SCHEMBL6313790

SCHEMBL6313790

C1CC(NCC23CC4CC(CC(C4)C2)C3)CCN1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.44
EPHX1 P07099 3/20 0.44
P2RX7 Q99572 5/20 0.42
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
GNAI3 P08754 2/20 0.37
GNAO1 P09471 2/20 0.37
GNAI1 P63096 2/20 0.37
HSD17B10 Q99714 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
KMT2A Q03164 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14993977 0.86 ALDH1A1 (0.47) EPHX2P2RX7ALDH1A1TSHRHSD17B10
SCHEMBL19173341 0.74 GRIN2D (0.46) ALDH1A1KMT2AGRIN2DGRIN3BGRIN1
SCHEMBL4188081 0.70 EPHX1 (0.61) EPHX2EPHX1P2RX7ALDH1A1GNAI3
SCHEMBL4228257 0.68 EPHX1 (0.64) EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL13703407 0.68 GNAI3 (0.43) EPHX1GNAI3GNAO1GNAI1DPP7
Hydrochloric Acid SCHEMBL7247543 0.68 EPHX1 (0.45) EPHX2EPHX1P2RX7GRIN2DGRIN3B
SCHEMBL28834622 0.67 ALDH1A1 (0.36) EPHX2ALDH1A1TSHRHSD17B10GRIN2D
SCHEMBL5144107 0.67 EPHX1 (0.61) EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL1780950 0.66 L3MBTL1 (0.43) EPHX2EPHX1P2RX7ALDH1A1TSHR
SCHEMBL1678051 0.65 EPHX2 (0.47) EPHX2P2RX7ALDH1A1KMT2AGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113414-A1 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens CELLTECH R&D LIMITED (GB) 2005-05-26 US disclosed
EP-1478359-A1 PIPERIDIN-4-YL UREA DERIVATIVES AND RELATED COMPOUNDS AS CHEMOKINE RECEPTOR INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Celltech R & D Limited (GB) 2004-11-24 EP disclosed
WO-2003070242-A1 PIPERIDIN-4-YL UREA DERIVATIVES AND RELATED COMPOUNDS AS CHEMOKINE RECEPTOR INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES CELLTECH R & D LIMITED (GB) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113414-A1 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens CXCR3, ACKR3, CCR1 EPHX2 1395/4885EPHX1 1025/4885P2RX7 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.